Skip Navigation


Rheumatology Advance Access originally published online on November 22, 2005
Rheumatology 2006 45(4):481-484; doi:10.1093/rheumatology/kei190
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/4/481    most recent
kei190v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lodde, B. M.
Right arrow Articles by Pillemer, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lodde, B. M.
Right arrow Articles by Pillemer, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Published by Oxford University Press 2005.

Serum lipid levels in Sjögren's syndrome

B. M. Lodde1,2, V. Sankar1,*, M. R. Kok1,2, R. A. Leakan1, P. P. Tak2 and S. R. Pillemer1,{dagger}

1 Gene Therapy and Therapeutics Branch/National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA and 2 Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands.

Correspondence to: B. M. Lodde, GTTB/NIDCR, National Institutes of Health, 10 Center Drive, Room 1N114, MSC 1190, Bethesda, MD 20892–1190, USA. E-mail: blodde{at}mail.nih.gov


   Abstract
Top
 Abstract
Introduction
 Patients and methods
 Results
 Discussion
 References
 
Objectives. Altered lipid levels may occur in autoimmune diseases, for example low cholesterol levels have been described in rheumatoid arthritis (RA). Serum lipid profiles in patients with Sjögren's syndrome (SS) have not been investigated. We hypothesized decreased lipid levels in SS patients and an inverse relationship with disease activity.

Methods. Serum lipid levels [total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides] and additional data regarding disease measures (clinical immunology parameters, focus score from labial salivary gland biopsy, salivary flow and ophthalmological measures) were available for 46 primary SS patients and 12 xerostomic controls.

Results. Significant differences between SS patients and controls means (S.D.) were seen for HDL (P = 0.04) and total cholesterol (P = 0.02). LDL (P = 0.12) and triglyceride (P = 0.08) levels were not different. In SS patients, but not in controls, total cholesterol (P = 0.003) and HDL cholesterol (P = 0.003) predicted immunoglobulin G levels. Anti-SSA antibodies were related to a lower total cholesterol (P = 0.02) and anti-SSB antibodies to a lower HDL cholesterol level (P = 0.0497).

Conclusions. Significant differences were seen in serum lipid levels of primary SS patients and these were associated with serological measures of inflammation. Our results are comparable to earlier findings in RA patients and raise questions related to adverse cardiovascular consequences in SS.

KEY WORDS: Sjögren's syndrome, Cholesterol, HDL, Inflammation, Cardiovascular disease


   Introduction
Top
 Abstract
 Introduction
Patients and methods
 Results
 Discussion
 References
 
Altered lipid levels have been reported in patients with active autoimmune disorders. For example, several groups have reported on various changes in lipid levels in rheumatoid arthritis (RA) patients [1–9]. A decreased level of high-density lipoprotein (HDL) cholesterol with inflammation seems to be a consistent finding. Additionally, a higher risk of atherosclerosis and cardiovascular mortality is seen in RA [10]. Increased lipid levels have been found in patients with systemic lupus erythematosus (SLE), where disease activity may be related to increases in levels of triglyceride and very low-density lipoprotein (VLDL) cholesterol, while HDL cholesterol was decreased. Inflammatory proteins and autoantibodies in SLE are possibly associated with an increased risk of cardiovascular disease [11, 12].

Sjögren's syndrome (SS) is a systemic autoimmune disease mainly characterized by ocular and oral dryness (keratoconjunctivitis sicca and xerostomia). There is a distinction between primary SS and secondary SS, the latter developing in the presence of other connective tissue diseases, like SLE or RA [13]. Sjögren's syndrome occurs predominantly in peri- and post-menopausal women. Detailed investigations of serum lipid profiles or the prevalence of atherosclerosis in patients with SS have yet to be performed. One of the few studies related to this topic has concentrated on the distinction between pseudo-Sjögren's syndrome in patients with hyperlipidaemia and genuine SS using magnetic resonance imaging (MRI) [14].

In the present study, we sought to compare serum lipid profiles in patients with primary SS and non-SS xerostomic patients. We hypothesized that serum lipid levels in SS patients would be lower than those in xerostomic controls. Additionally, we investigated the relationship between serum lipid levels and measures of inflammatory disease activity in patients with SS. Based on reports for other autoimmune diseases, we postulated an inverse relationship for such measures with lipid levels.


   Patients and methods
Top
 Abstract
 Introduction
 Patients and methods
Results
 Discussion
 References
 
We abstracted data from our database of SS patients in the National Institute of Dental and Craniofacial Research (NIDCR) Sjögren's Syndrome Clinic. The database contains uniform and systematically collected information of all patients and is referral based. The selected patients were participants in research protocols, which had been approved by the Institutional Review Board of the NIDCR at the National Institutes of Health. The subjects’ written consent was obtained according to the Declaration of Helsinki. The diagnosis of primary SS was based on the 2002 American–European Consensus Classification Criteria [15]. The control group consisted of xerostomic patients, i.e. those who complained of a dry mouth and were screened for SS but did not meet the criteria. Patients with other connective tissue diseases, sarcoidosis, amyloidosis, diabetes mellitus, cardiovascular disease, thyroid disease, hereditary hyperlipidaemia or use of cholesterol-lowering medication were excluded. Lipid profile data, i.e. total cholesterol, HDL cholesterol, LDL cholesterol and triglyceride serum levels (determined after at least 8 h of fasting), were available for 46 SS patients and 12 xerostomic controls seen at our clinic between 1997 and 2003.

Demographic information (age, gender and race) was collected. Data regarding disease activity were obtained at the same time and included objective ophthalmological measures (Schirmer's I test and ocular dye tests applying the Van Bijsterveld score [16]), salivary flow rates for the left and right parotid and submandibular/sublingual glands (both under unstimulated and 2% citric acid stimulated conditions), labial minor salivary gland biopsy focus scores and clinical immunology measures including immunoglobulin levels [immunoglobulin (Ig) G, IgA, IgM], autoantibodies [antinuclear antibodies (ANA), anti-SSA, anti-SSB, anti-deoxyribonucleic acid (anti-DNA), anti-ribonucleoprotein (anti-RNP), anti-Sm, anticardiolipin-IgM/IgG, rheumatoid factor (RF)] and acute phase reactants [C3, C4, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)]. For data analysis the statistical computer program SAS was used. The analyses, performed at one time, included descriptive statistics, Student's t-tests, Fisher's exact tests, non-parametric analysis of variance (ANOVA) using the Kruskal–Wallis test, and linear regression models.

Using the Adult Treatment Panel III (ATP III) guidelines of the USA's National Cholesterol Education Program, we considered a HDL cholesterol level of less than 50 mg/dl (SI 1.295 mmol/l) in women as a high-risk factor for coronary heart disease [17]. Non-HDL cholesterol (total cholesterol minus HDL cholesterol) has been identified as a secondary target of therapy in persons with high triglycerides [≥200 mg/dl (SI 2.26 mmol/l)] [17]. Recently, non-HDL cholesterol was shown to be a better predictor of cardiovascular mortality than LDL cholesterol [18]. We therefore also included non-HDL cholesterol levels in our analysis.


   Results
Top
 Abstract
 Introduction
 Patients and methods
 Results
Discussion
 References
 
The mean (S.D.) age of SS patients was 53.5 (12.3) yr and 52.5 (7.8) yr for the xerostomic controls (P = 0.79). The mean (S.D.) disease duration (duration between time of symptom onset and data collection) for SS patients of 12.0 (8.4) yr was greater than for the xerostomic controls, which was 6.5 (5.2) yr (P = 0.04). Ethnicity did not differ between groups (P = 0.5). All subjects in this study were female.

Table 1 shows a summary of the various clinical chemistry measures examined in SS patients and xerostomic controls. We observed statistically significant differences in levels of certain serum lipids between SS patients and xerostomic controls. Thus, the mean (S.D.) level for total cholesterol in SS patients and controls was, respectively, 4.79 (0.97) vs 5.49 (0.69) mmol/l (P = 0.02) and for HDL cholesterol 1.41 (0.40) vs 1.72 (0.52) mmol/l (P = 0.04). There were no statistically significant differences in mean LDL cholesterol (P = 0.12), triglyceride (P = 0.08) or non-HDL cholesterol levels (P = 0.19) between the groups. Mean CRP levels showed significant differences: 1.75 (5.49) vs 0.00 (0.00) mg/l for SS patients and controls (P = 0.048), respectively. The total cholesterol/HDL ratio was not increased in SS patients compared with controls [3.66 (1.13) vs 3.43 (0.94), P = 0.55]. In the SS patients examined here, 39.0% had high-risk HDL levels (ATP III criteria) compared with 18.2% of the xerostomic controls (P = 0.29). Additionally, 46.9% of patients with anti-SSA antibodies had high-risk HDL levels, where 15.0% of seronegative patients were at risk (P = 0.03) (not shown).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Characteristics of SS patient group (SS+) and xerostomic controls (SS–)

 
In SS patients, but not in controls, total cholesterol (P = 0.003), HDL cholesterol (P = 0.003), focus scores (P = 0.0006) and RF (P<0.0001) predicted IgG levels by linear regression (Table 2). Total cholesterol levels were significantly lower in SS patients with anti-SSA ({chi}2 = 5.37, P = 0.02), but not anti-SSB antibodies ({chi}2 = 1.16, P = 0.28). Lower HDL cholesterol levels were seen in patients with anti-SSB ({chi}2 = 3.85, P = 0.0497), but not anti-SSA antibodies ({chi}2 = 3.21, P = 0.07). Focus scores, CRP, ESR, C3 or C4 levels were not predicted by either HDL or total cholesterol (P values between 0.08 and 0.9) in a linear regression model (data not shown).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Predictors of focus score and IgG levels in SS patients (SS+) and xerostomia controls (SS–)

 

   Discussion
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
References
 
This is the first report to examine the serum lipid profile of patients with primary SS. In the current study, HDL and total cholesterol levels were significantly lower in SS patients diagnosed using the new American–European Consensus Criteria than in xerostomic controls. In SS patients, low HDL and total cholesterol levels were associated with tissue inflammation and serological measures: serum IgG levels were predicted by both HDL and total cholesterol levels. Immunoglobulin G is an important disease marker in SS [19] and is positively associated with focus scores [20]. We were unable to find useful information in the literature on the association discovered here between anti-SSA/B antibodies and cholesterol levels. However, the presence of these specific antibodies may reflect SS disease activity in general. Compared with the female adult US population of identical age [21], our xerostomic controls had similar total and LDL cholesterol, higher HDL cholesterol and lower triglyceride levels; SS patients showed lower mean total, LDL cholesterol and triglyceride, and similar HDL cholesterol levels. Previous investigations involved lipid infiltration of the major salivary glands of SS patients visualized by MRI and labial gland biopsies, but serum lipid levels were not studied [14, 22]. A study by Matsuo et al. [23] examined systemic disease activity in RA patients with ocular complications. The authors found that the presence of keratoconjunctivitis sicca in patients with secondary SS was related to higher titres of RF, higher levels of IgM and lower HDL cholesterol levels.

Overall, our results for HDL and total cholesterol levels in SS patients are comparable to earlier findings in RA [1–9, 24, 25]. The acute-phase response in RA is thought to be at least partially responsible for the phenomenon of decreased HDL cholesterol levels [26, 27]. In RA, decreased lipid levels tended to predict cardiovascular morbidity and mortality [28, 29]. The hypothesized pathogenesis of this vascular damage in RA and SLE suggested by different authors [11, 29] is continuous endothelial activation due to several possible factors, including an up-regulation of adhesion molecules on endothelial cells by inflammatory cytokines and the presence of immune complexes and autoantibodies. This may lead to a prematurely aging, dysfunctional vasculature, rendering it more susceptible to traditional cardiovascular risk factors, such as cholesterol levels, than in the general population. For example, Svenson et al. [1] suggested that the degree of inflammatory activity determined the lipoprotein alterations observed in their patients with untreated chronic inflammatory arthritides. Furthermore, patients with untreated, active RA show altered lipoprotein patterns that may possibly expose them to a higher risk of atherosclerosis. Since we observed the same alteration in lipid profiles of SS patients, this raises questions about the prevalence of atherosclerosis and subsequent cardiovascular events in SS. However, this has not been studied thus far in SS.

Effective treatment of an inflammatory process may prove beneficial for dyslipoproteinaemia and possibly the risk of cardiovascular disease (CVD) and related mortality. Both Svenson et al. [30] and Park et al. [25] investigated the effects of anti-rheumatic therapy on serum lipid levels in newly diagnosed and untreated RA patients. Active RA was associated with an adverse lipid profile that improved significantly upon effective treatment of RA with methotrexate, other disease-modifying anti-rheumatic drugs and/or prednisolone, suggesting it was the decrease in RA disease activity that reversed the altered lipid profiles.

Interestingly, several recent studies have tested whether HMG-CoA reductase inhibitors, such as atorvastatin and simvastatin, had pleiotropic immunomodulatory effects in RA patients [31, 32] and mouse models for multiple sclerosis [33] and inflammatory arthritis [34]. It appears that statins could inhibit developing and clinically evident disease through suppression of humoral and cellular immune responses, with no or only small changes in serum lipid levels. However, a new study indicated that increased glucocorticoid levels, induced by the statin treatment, could cause the perceived beneficial effect [35]. This raises the possibility that these drugs may have a role in the treatment of autoimmune diseases, including Sjögren's syndrome; further research could lead to more insights.

Recently, it has been suggested that the CRP level was a stronger predictor of CVD than the level of LDL cholesterol [36]. Park et al. [5] found a negative correlation between HDL cholesterol and CRP in their study on lipid profiles in untreated RA patients, again suggesting an altered lipid profile during an inflammatory condition. In the current study we could not confirm this finding, which could be due to the relatively low mean CRP levels, with only six SS patients having an elevated CRP level, or an absence of an association between lipids and CRP levels in SS. In general, CRP levels tend to be a less useful marker of disease activity than ESR levels in SS [37]. Here, ESR did not correlate with cholesterol levels either. Although elevated non-HDL cholesterol has been shown to be a better predictor of cardiovascular mortality than LDL cholesterol [18], we found no differences between SS patients and xerostomic controls for LDL or non-HDL cholesterol. However, HDL and total cholesterol levels were significantly decreased in SS patients, suggesting that a lower total cholesterol reflects a low HDL cholesterol level. Non-HDL levels in rheumatological diseases have not been studied so far. Therefore, no conclusions can be drawn regarding the cardiovascular effects of altered non-HDL levels in SS or RA.

In conclusion, HDL and total cholesterol levels were significantly lower in primary SS patients than xerostomic controls, and in SS patients low total and HDL cholesterol levels were associated with serologically active disease. These results are comparable with earlier findings in RA. Since decreased cholesterol levels tended to predict cardiovascular morbidity and mortality in RA, the finding of an altered lipid profile in SS raises questions about the potential for adverse cardiovascular consequences in this disease.
Figure 1


   Acknowledgments
 
MRK is supported by the Dutch Arthritis Foundation project NR 02–01–302.

The authors have declared no conflicts of interest.


   Notes
 
*Present address: Division of Oral Medicine/Dental Diagnostic Science, Health Science Center/The University of Texas, San Antonio, Texas, USA. Back

{dagger}Present address: Clinical Development Immunological and Inflammatory Diseases, MedImmune, Inc., Gaithersburg, Maryland, USA. Back


   References
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
 References
 

  1. Svenson KL, Lithell H, Hallgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987;147:1912–16.[Abstract/Free Full Text]
  2. Lakatos J, Harsagyi A. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988;21:93–6.[CrossRef][Web of Science][Medline]
  3. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:366–8.[Abstract/Free Full Text]
  4. Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992;22:172–8.[CrossRef][Web of Science][Medline]
  5. Park YB, Lee SK, Lee WK et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701–4.[Web of Science][Medline]
  6. Vottery R, Saigal R, Singhal N, Gupta BS. Lipid profile in rheumatoid arthritis and its relation to disease activity. J Assoc Physicians India 2001;49:1188–90.[Medline]
  7. Hurt-Camejo E, Paredes S, Masana L et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001;44:2761–7.[CrossRef][Web of Science][Medline]
  8. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004;31:1746–53.[Abstract/Free Full Text]
  9. Dursunoglu D, Evrengul H, Polat B et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2004;25:241–5.
  10. Jacobsson LT, Turesson C, Hanson RL et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001;44:1170–6.[CrossRef][Medline]
  11. Meyer O. Atherosclerosis and connective tissue diseases. Joint Bone Spine 2001;68:564–75.[CrossRef][Web of Science][Medline]
  12. Gordon C. Long-term complications of systemic lupus erythematosus. Rheumatology 2002;41:1095–100.[Free Full Text]
  13. Moutsopoulos HM. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162–5.[CrossRef][Web of Science][Medline]
  14. Izumi M, Hida A, Takagi Y, Kawabe Y, Eguchi K, Nakamura T. MR imaging of the salivary glands in sicca syndrome: comparison of lipid profiles and imaging in patients with hyperlipidemia and patients with Sjogren's syndrome. Am J Roentgenol 2000;175:829–34.[Abstract/Free Full Text]
  15. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.[Abstract/Free Full Text]
  16. van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol 1969;82:10–14.[Abstract/Free Full Text]
  17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97.[Free Full Text]
  18. Hirsch GA, Vaid N, Blumenthal RS. Perspectives: the significance of measuring non-HDL-cholesterol. Prev Cardiol 2002;5:156–9.[Medline]
  19. Pertovaara M, Korpela M, Uusitalo H et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis 1999;58:423–7.[Abstract/Free Full Text]
  20. Brennan MT, Sankar V, Leakan RA et al. Risk factors for positive minor salivary gland biopsy findings in Sjogren's syndrome and dry mouth patients. Arthritis Rheum 2002;47:189–95.[Medline]
  21. Johnson CL, Rifkind BM, Sempos CT et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. J Am Med Assoc 1993;269:3002–8.[Abstract/Free Full Text]
  22. Izumi M, Eguchi K, Nakamura H, Nagataki S, Nakamura T. Premature fat deposition in the salivary glands associated with Sjogren syndrome: MR and CT evidence. Am J Neuroradiol 1997;18:951–8.[Abstract]
  23. Matsuo T, Kono R, Matsuo N et al. Incidence of ocular complications in rheumatoid arthritis and the relation of keratoconjunctivitis sicca with its systemic activity. Scand J Rheumatol 1997;26:113–16.[Medline]
  24. Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19:324–5.[CrossRef][Web of Science][Medline]
  25. Park YB, Choi HK, Kim MY et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188–93.[CrossRef][Web of Science][Medline]
  26. Hosoai H, Webb NR, Glick JM et al. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res 1999;40:648–53.[Abstract/Free Full Text]
  27. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.[CrossRef][Medline]
  28. Wallberg-Jonsson S, Cederfelt M, Rantapaa Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000;27:71–5.[Web of Science][Medline]
  29. Jonsson SW, Backman C, Johnson O et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001;28:2597–602.[Abstract/Free Full Text]
  30. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987;147:1917–20.[Abstract/Free Full Text]
  31. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607–11.[Abstract/Free Full Text]
  32. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015–21.[CrossRef][Web of Science][Medline]
  33. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78–84.[CrossRef][Medline]
  34. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524–30.[Abstract/Free Full Text]
  35. Palmer G, Chobaz V, Talabot-Ayer D et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum 2004;50:4051–9.[Medline]
  36. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65.[Abstract/Free Full Text]
  37. Moutsopoulos HM, Elkon KB, Mavridis AK, Acritidis NC, Hughes GR, Pepys MB. Serum C-reactive protein in primary Sjogren's syndrome. Clin Exp Rheumatol 1983;1:57–8.[Medline]
Submitted 6 March 2005; Accepted 6 October 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
T. Kimura, C. Mogi, H. Tomura, A. Kuwabara, D.-S. Im, K. Sato, H. Kurose, M. Murakami, and F. Okajima
Induction of Scavenger Receptor Class B Type I Is Critical for Simvastatin Enhancement of High-Density Lipoprotein-Induced Anti-Inflammatory Actions in Endothelial Cells
J. Immunol., November 15, 2008; 181(10): 7332 - 7340.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Gerli, E. Bartoloni Bocci, G. Vaudo, S. Marchesi, C. Vitali, and Y. Shoenfeld
Traditional cardiovascular risk factors in primary Sjogren's syndrome--role of dyslipidaemia
Rheumatology, December 1, 2006; 45(12): 1580 - 1581.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
B. M. Lodde, V. Sankar, M. R. Kok, R. A. Leakan, P. P. Tak, and S. R. Pillemer
Re: Traditional cardiovascular risk factors in primary Sjogren's syndrome: role of dyslipidaemia
Rheumatology, December 1, 2006; 45(12): 1581 - 1582.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/4/481    most recent
kei190v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lodde, B. M.
Right arrow Articles by Pillemer, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lodde, B. M.
Right arrow Articles by Pillemer, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?